EATG » PrEP

PrEP

‘In complete shock’: Sydney man contracts HIV despite taking PrEP drug

A Sydney man has been diagnosed with HIV despite taking a "game-changing" pre-exposure prophylaxis medication known as PrEP. Steven Spencer, 27, tested positive for HIV in December, despite using PrEP…

CROI 2019: On-Demand PrEP With TDF/FTC Not Associated With Clinically Relevant Decline in Kidney Function

On-demand pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is not associated with a significant relevant in kidney function, especially among young people with low pill use and high…

CROI 2019: Urine test can provide accurate point-of-care results about PrEP adherence

A point-of-care urine test can accurately determine if a person if adherent to tenofovir-based pre-exposure prophylaxis (PrEP), according to research presented to the recent Conference on Retroviruses and Opportunistic Infections…

HIV i-Base: HTB, first reports from CROI 2019; Fit for Purpose report 2019 released

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. This edition of HTB includes the first reports from CROI 2019, with additional reports following in subsequent issues.…

CROI 2019: TAF: Quick-dissolve combination PrEP insert is effective against HIV infections in monkeys; intermittent solo pill less so

Two studies in monkeys of experimental pre-exposure prophylaxis (PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing results when presented at last week’s CROI conference. As a third study…

CROI 2019: People stay on PrEP for 14 months on average in the US, study finds

Young, rural, black, female and Medicaid-insured users stay on it for half as long Whether HIV pre-exposure prophylaxis (PrEP) is effective depends on whether people take it appropriately, at the…

CROI 2019: NATAP reports

Conference on Retroviruses and Opportunistic Infections (CROI), 4-7 March 2019, Seattle, Washington, USA HIV tied to almost 2-fold lower breast cancer survival  Probiotic does not alter inflammation/activation markers in group…

CROI 2019: PrEP use in persons with undetected HIV infections contributes to resistance

With antimicrobial resistance at the top of the World Health Organization’s top 10 global health threats of 2019, it’s only natural that resistance is also at top of mind for…

CROI 2019: Women, young patients less likely to persistently use PrEP

SEATTLE — Women and young patients are less likely to persistently use pre-exposure prophylaxis, or PrEP, for HIV prevention compared with men and older users, according to study data presented…

CROI 2019: Gilead announces data on Descovy for PrEP

Gilead announces data demonstrating non-inferiority of once-daily Descovy® vs. once-daily Truvada® for prevention of HIV infection – DISCOVER trial meets primary and secondary endpoints and will support supplemental regulatory filing…

1 2 3 42